Dyskinesia - Pipeline Review, H2 2019

Dyskinesia - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2019, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 16, 9, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Dyskinesia - Overview
Dyskinesia - Therapeutics Development
Dyskinesia - Therapeutics Assessment
Dyskinesia - Companies Involved in Therapeutics Development
Dyskinesia - Drug Profiles
Dyskinesia - Dormant Projects
Dyskinesia - Discontinued Products
Dyskinesia - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Dyskinesia, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 9: Products under Development by Universities/Institutes, H2 2019
Table 10: Number of Products by Stage and Target, H2 2019
Table 11: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 12: Number of Products by Stage and Mechanism of Action, H2 2019
Table 13: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 14: Number of Products by Stage and Route of Administration, H2 2019
Table 15: Number of Products by Stage and Molecule Type, H2 2019
Table 16: Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2019
Table 17: Dyskinesia - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
Table 18: Dyskinesia - Pipeline by Astraea Therapeutics LLC, H2 2019
Table 19: Dyskinesia - Pipeline by Cadent Therapeutics Inc, H2 2019
Table 20: Dyskinesia - Pipeline by Cannabis Science Inc, H2 2019
Table 21: Dyskinesia - Pipeline by Cavion LLC, H2 2019
Table 22: Dyskinesia - Pipeline by Cerevance Inc, H2 2019
Table 23: Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2019
Table 24: Dyskinesia - Pipeline by Contera Pharma ApS, H2 2019
Table 25: Dyskinesia - Pipeline by DanPET AB, H2 2019
Table 26: Dyskinesia - Pipeline by EpiVax Inc, H2 2019
Table 27: Dyskinesia - Pipeline by GW Pharmaceuticals Plc, H2 2019
Table 28: Dyskinesia - Pipeline by H. Lundbeck AS, H2 2019
Table 29: Dyskinesia - Pipeline by Hua Medicine Shanghai Ltd, H2 2019
Table 30: Dyskinesia - Pipeline by Ipsen SA, H2 2019
Table 31: Dyskinesia - Pipeline by IRLAB Therapeutics AB, H2 2019
Table 32: Dyskinesia - Pipeline by Junaxo Inc, H2 2019
Table 33: Dyskinesia - Pipeline by Med-Life Discoveries LP, H2 2019
Table 34: Dyskinesia - Pipeline by Medytox Inc, H2 2019
Table 35: Dyskinesia - Pipeline by Melior Pharmaceuticals II LLC, H2 2019
Table 36: Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2019
Table 37: Dyskinesia - Pipeline by MitoDys Therapeutics Ltd, H2 2019
Table 38: Dyskinesia - Pipeline by Motac Neuroscience Ltd, H2 2019
Table 39: Dyskinesia - Pipeline by NeurAxon Pharma Inc, H2 2019
Table 40: Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Table 41: Dyskinesia - Pipeline by Neurocea Pharmaceuticals, H2 2019
Table 42: Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2019
Table 43: Dyskinesia - Pipeline by Neurolixis Inc, H2 2019
Table 44: Dyskinesia - Pipeline by Newron Pharmaceuticals SpA, H2 2019
Table 45: Dyskinesia - Pipeline by Nissan Chemical Corp, H2 2019
Table 46: Dyskinesia - Pipeline by OB Pharmaceuticals, H2 2019
Table 47: Dyskinesia - Pipeline by Peptron Inc, H2 2019
Table 48: Dyskinesia - Pipeline by PolyCore Therapeutics LLC, H2 2019
Table 49: Dyskinesia - Pipeline by Praxis Precision Medicines Australia Pty Ltd, H2 2019
Table 50: Dyskinesia - Pipeline by Prilenia Therapeutics Development Ltd, H2 2019
Table 51: Dyskinesia - Pipeline by Revance Therapeutics Inc, H2 2019
Table 52: Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2019
Table 53: Dyskinesia - Pipeline by SalubRx Therapeutics Inc, H2 2019
Table 54: Dyskinesia - Pipeline by Sinopia Biosciences Inc, H2 2019
Table 55: Dyskinesia - Pipeline by SOM Biotech SL, H2 2019
Table 56: Dyskinesia - Pipeline by Sosei Heptares, H2 2019
Table 57: Dyskinesia - Pipeline by Trevi Therapeutics Inc, H2 2019
Table 58: Dyskinesia - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2019
Table 59: Dyskinesia - Pipeline by VistaGen Therapeutics Inc, H2 2019
Table 60: Dyskinesia - Dormant Projects, H2 2019
List of Figures
Figure 1: Number of Products under Development for Dyskinesia, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook